Clinical Research Papers:
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
Metrics: PDF 1590 views | HTML 2797 views | ?
Shuping Xu1,2, Mayra Ramos-Suzarte3, Xianhong Bai2, Binghe Xu1
1Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
2Department of Medical Affairs, Biotech Pharmaceuticals Co., Ltd., P. R. China
3Department of Clinical Research, Center of Molecular Immunology, Havana, Cuba
Binghe Xu, email: [email protected]
Keywords: nimotuzumab, monoclonal antibody, chemotherapy, advanced cancer
Received: December 17, 2015 Accepted: March 02, 2016 Published: March 31, 2016
Nimotuzumab is a humanized anti-EGFR IgG1 monoclonal antibody and demonstrates a better safety profile than other anti-EGFR antibodies due to its intermediate affinity. Since it was approved in China for the treatment of nasopharyngeal cancer (NPC), it has been widely used in NPC and in many clinical trials for other cancer types. However, the optimal dose and administration frequency of nimotuzumab that should be used and which kind of cancer patients will be more benefited from nimotuzumab is still unknown. In this retrospective study, 205 advanced cancer patients with colorectal cancer, esophageal cancer, head and neck cancer, gastric cancer, non-small cell lung cancer, or other cancers from mainland China, treated with nimotuzumab in combination with chemotherapy, were enrolled. Over 60% of these patients received nimotuzumab > 6 doses and ≥ 400 mg/week as maintenance therapy. It was well tolerated in real-life patients. This report demonstrates that age, sex and previous treatment might be potential predictive factors for survival, and patients received nimotuzumab > 6 doses and > 200 mg/week might benefit more from nimotuzumab therapy. Using these factors for stratification analysis may form a predictive differential clinical strategy for nimotuzumab to maximize the benefit in patients with different epithelial tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.